{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:25Z","timestamp":1784977225199,"version":"3.55.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01449-5","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:51:58Z","timestamp":1784969518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Lipid Burden and the Role of Non-LDL Biomarkers in Stroke Risk Stratification"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-6080","authenticated-orcid":false,"given":"Sean Michael","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koto","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rostanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"9","key":"1449_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. JACC. 2023;82(9):833\u2013955.","journal-title":"JACC"},{"issue":"10199","key":"1449_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(19)31950-6","volume":"394","author":"KK Ray","year":"2019","unstructured":"Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019;394(10199):697\u2013708.","journal-title":"Lancet"},{"issue":"5","key":"1449_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/jamainternmed.2022.0134","volume":"182","author":"P Byrne","year":"2022","unstructured":"Byrne P, Demasi M, Jones M, Smith SM, O\u2019Brien KK, DuBroff R. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022;182(5):474\u201381.","journal-title":"JAMA Intern Med"},{"issue":"10B","key":"1449_CR4","doi-asserted-by":"publisher","first-page":"T53","DOI":"10.1016\/S0002-9149(98)00727-9","volume":"82","author":"TR Pedersen","year":"1998","unstructured":"Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol. 1998;82(10B):T53\u20136.","journal-title":"Am J Cardiol"},{"issue":"10513","key":"1449_CR5","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(25)01330-3","volume":"406","author":"GBD 2023 Demographics Collaborators","year":"2025","unstructured":"GBD 2023 Demographics Collaborators. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950\u20132023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1731\u2013810.","journal-title":"Lancet"},{"issue":"11","key":"1449_CR6","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1161\/STROKEAHA.115.011164","volume":"46","author":"S Yaghi","year":"2015","unstructured":"Yaghi S, Elkind MSV. Lipids and Cerebrovascular Disease. Stroke. 2015;46(11):3322\u20138.","journal-title":"Stroke"},{"issue":"1","key":"1449_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1910355","volume":"382","author":"P Amarenco","year":"2020","unstructured":"Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B\u00e9jot Y, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382(1):9\u201319.","journal-title":"N Engl J Med"},{"key":"1449_CR8","doi-asserted-by":"crossref","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2021 July;52(7):e364\u2013467.","DOI":"10.1161\/STR.0000000000000375"},{"issue":"15","key":"1449_CR9","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.jacc.2019.12.072","volume":"75","author":"HC Diener","year":"2020","unstructured":"Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020;75(15):1804\u201318.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1449_CR10","first-page":"e404","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, Arteriosclerosis, et al. Thromb Vascular Biology. 2023;43(10):e404\u201342.","journal-title":"Thromb Vascular Biology"},{"issue":"14","key":"1449_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.119.044282","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Smith SC, Stone NJ, Grundy SM. Secondary Prevention for Atherosclerotic Cardiovascular Disease. Circulation. 2020;141(14):1121\u20133.","journal-title":"Circulation"},{"issue":"5","key":"1449_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(04)00734-3","volume":"3","author":"P Amarenco","year":"2004","unstructured":"Amarenco P, Lavall\u00e9e P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004;3(5):271\u20138.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1449_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC, L\u00fcscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113\u201331.","journal-title":"Eur Heart J"},{"issue":"11","key":"1449_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","volume":"77","author":"CDL Johannesen","year":"2021","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021;77(11):1439\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1449_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/archneur.64.1.93","volume":"64","author":"G Razay","year":"2007","unstructured":"Razay G, Vreugdenhil A, Wilcock G. The Metabolic Syndrome and Alzheimer Disease. Arch Neurol. 2007;64(1):93\u20136.","journal-title":"Arch Neurol"},{"issue":"3","key":"1449_CR16","doi-asserted-by":"publisher","first-page":"e0264634","DOI":"10.1371\/journal.pone.0264634","volume":"17","author":"T L\u00f3pez-Jim\u00e9nez","year":"2022","unstructured":"L\u00f3pez-Jim\u00e9nez T, Duarte-Salles T, Plana-Ripoll O, Recalde M, Xavier-Cos F, Puente D. Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study. PLoS ONE. 2022;17(3):e0264634.","journal-title":"PLoS ONE"},{"issue":"11","key":"1449_CR17","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/dc12-0336","volume":"35","author":"K Esposito","year":"2012","unstructured":"Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402\u201311.","journal-title":"Diabetes Care"},{"key":"1449_CR18","doi-asserted-by":"crossref","unstructured":"Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113\u201332.","DOI":"10.1016\/j.jacc.2010.05.034"},{"issue":"18","key":"1449_CR19","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1001\/jama.2008.621","volume":"300","author":"JJ Freiberg","year":"2008","unstructured":"Freiberg JJ, Tybj\u00e6rg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population. JAMA. 2008;300(18):2142\u201352.","journal-title":"JAMA"},{"issue":"24","key":"1449_CR20","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1161\/hc4901.100384","volume":"104","author":"D Tanne","year":"2001","unstructured":"Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood Lipids and First-Ever Ischemic Stroke\/Transient Ischemic Attack in the Bezafibrate Infarction Prevention (BIP) Registry. Circulation. 2001;104(24):2892\u20137.","journal-title":"Circulation"},{"issue":"11","key":"1449_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/01.wnl.0000294323.48661.a9","volume":"70","author":"OY Bang","year":"2008","unstructured":"Bang OY, Saver JL, Liebeskind DS, Pineda S, Ovbiagele B. Association of serum lipid indices with large artery atherosclerotic stroke. Neurology. 2008;70(11):841\u20137.","journal-title":"Neurology"},{"key":"1449_CR22","doi-asserted-by":"crossref","unstructured":"Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG\/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243\u201350.","DOI":"10.1016\/j.atherosclerosis.2015.06.057"},{"issue":"4","key":"1449_CR23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.numecd.2023.01.003","volume":"33","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jin X, Fu K, Li J, Xue W, Tian L, et al. Non-traditional lipid profiles and the risk of stroke: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2023;33(4):698\u2013714.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"1449_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.numecd.2021.11.005","volume":"32","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chang Z, Liu Y, Zhao Y, Fu J, Zhang Y, et al. Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis. 2022;32(2):318\u201329.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"1449_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/dc16-1958","volume":"40","author":"JS Lee","year":"2017","unstructured":"Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. Diabetes Care. 2017;40(4):529\u201337.","journal-title":"Diabetes Care"},{"issue":"8","key":"1449_CR26","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.numecd.2022.05.002","volume":"32","author":"F Sato","year":"2022","unstructured":"Sato F, Nakamura Y, Kayaba K, Ishikawa S. TG\/HDL-C ratio as a predictor of stroke in the population with healthy BMI: The Jichi Medical School Cohort Study. Nutr Metab Cardiovasc Dis. 2022;32(8):1872\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1449_CR27","doi-asserted-by":"crossref","unstructured":"Zhou L, Mai J, Li Y, Guo M, Wu Y, Gao X et al. Triglyceride to high-density lipoprotein cholesterol ratio and risk of atherosclerotic cardiovascular disease in a Chinese population. Nutr Metab Cardiovasc Dis. 2020;30(10):1706\u201313.","DOI":"10.1016\/j.numecd.2020.05.009"},{"issue":"1","key":"1449_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12944-022-01683-1","volume":"21","author":"M Tang","year":"2022","unstructured":"Tang M, Zhao Q, Yi K, Wu Y, Xiang Y, Cui S, et al. Association between four nontraditional lipids and ischemic stroke: a cohort study in Shanghai, China. Lipids Health Dis. 2022;21(1):72.","journal-title":"Lipids Health Dis"},{"key":"1449_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13098-024-01339-3","volume":"16","author":"S Zhang","year":"2024","unstructured":"Zhang S, Cao C, Han Y, Hu H, Zheng X. A nonlinear relationship between the triglycerides to high-density lipoprotein cholesterol ratio and stroke risk: an analysis based on data from the China Health and Retirement Longitudinal Study. Diabetol Metab Syndr. 2024;16:96.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"1449_CR30","first-page":"490","volume":"21","author":"MG Knight","year":"2011","unstructured":"Knight MG, Goedecke JH, Ricks M, Evans J, Levitt NS, Tulloch-Reid MK, et al. The TG\/HDL-C ratio does not predict insulin resistance in overweight women of African descent: a study of South African, African American and West African women. Ethn Dis. 2011;21(4):490\u20134.","journal-title":"Ethn Dis"},{"issue":"11","key":"1449_CR31","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1161\/STROKEAHA.114.006827","volume":"45","author":"JH Park","year":"2014","unstructured":"Park JH, Lee J, Ovbiagele B. Nontraditional serum lipid variables and recurrent stroke risk. Stroke. 2014;45(11):3269\u201374.","journal-title":"Stroke"},{"issue":"20","key":"1449_CR32","first-page":"2292","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides Cardiovasc Disease Circulation. 2011;123(20):2292\u2013333.","journal-title":"Triglycerides Cardiovasc Disease Circulation"},{"key":"1449_CR33","doi-asserted-by":"crossref","unstructured":"Li P, Cai J, Yuan S, Li Y, Shi H, Liang C et al. The relationship between triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular high risk: a cross-sectional investigation. Front Endocrinol (Lausanne). 2025;16:1688624.","DOI":"10.3389\/fendo.2025.1688624"},{"issue":"5","key":"1449_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/diagnostics13050929","volume":"13","author":"CE Kosmas","year":"2023","unstructured":"Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Pe\u00f1a Genao E, Guzman E, et al. The Triglyceride\/High-Density Lipoprotein Cholesterol (TG\/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics (Basel). 2023;13(5):929.","journal-title":"Diagnostics (Basel)"},{"issue":"24","key":"1449_CR35","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"1449_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11883-022-01006-w","volume":"24","author":"X Peng","year":"2022","unstructured":"Peng X, Wu H. Inflammatory Links Between Hypertriglyceridemia and Atherogenesis. Curr Atheroscler Rep. 2022;24(5):297\u2013306.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"1449_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547\u201363.","journal-title":"Circ Res"},{"issue":"1","key":"1449_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5853\/jos.2021.02831","volume":"24","author":"HJ Liang","year":"2022","unstructured":"Liang HJ, Zhang QY, Hu YT, Liu GQ, Qi R. Hypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke? J Stroke. 2022;24(1):21\u201340.","journal-title":"J Stroke"},{"issue":"4","key":"1449_CR39","doi-asserted-by":"publisher","first-page":"S527","DOI":"10.1055\/s-2001-15115","volume":"109","author":"A Silveira","year":"2001","unstructured":"Silveira A. Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes. 2001;109(4):S527\u2013532.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8328","key":"1449_CR40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(83)91849-4","volume":"321","author":"HCR Simpson","year":"1983","unstructured":"Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY. Lancet. 1983;321(8328):786\u201390.","journal-title":"Lancet"},{"issue":"20","key":"1449_CR41","doi-asserted-by":"publisher","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","volume":"11","author":"T Glavinovic","year":"2022","unstructured":"Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non\u2013High\u2010Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Association. 2022;11(20):e025858.","journal-title":"J Am Heart Association"},{"key":"1449_CR42","doi-asserted-by":"publisher","first-page":"100190","DOI":"10.1016\/j.ajpc.2021.100190","volume":"7","author":"AC Razavi","year":"2021","unstructured":"Razavi AC, Bazzano LA, He J, Krousel-Wood M, Dorans KS, Razavi MA, et al. Discordantly normal ApoB relative to elevated LDL-C in persons with metabolic disorders: A marker of atherogenic heterogeneity. Am J Prev Cardiol. 2021;7:100190.","journal-title":"Am J Prev Cardiol"},{"key":"1449_CR43","doi-asserted-by":"crossref","unstructured":"Sehayek D, Cole J, Bj\u00f6rnson E, Wilkins JT, Mortensen MB, Dufresne L et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology. 2025 July 1;19(4):844\u201359.","DOI":"10.1016\/j.jacl.2025.05.024"},{"key":"1449_CR44","doi-asserted-by":"crossref","unstructured":"Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pe\u00f1a JM et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. 2024 Sept 1;18(5):e647\u201363.","DOI":"10.1016\/j.jacl.2024.08.013"},{"issue":"11","key":"1449_CR45","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","volume":"77","author":"CDL Johannesen","year":"2021","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. JACC. 2021;77(11):1439\u201350.","journal-title":"JACC"},{"key":"1449_CR46","doi-asserted-by":"crossref","unstructured":"Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non\u2013high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410\u20138.","DOI":"10.1093\/eurheartj\/ehae258"},{"issue":"5","key":"1449_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","volume":"129","author":"S Mora","year":"2014","unstructured":"Mora S, Buring JE, Ridker PM. Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. Circulation. 2014;129(5):553\u201361.","journal-title":"Circulation"},{"issue":"12","key":"1449_CR48","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.jlr.2022.100299","volume":"63","author":"JT Wilkins","year":"2022","unstructured":"Wilkins JT, Ning H, Sniderman A, Stone N, Otvos J, Jacobs DR, et al. Analysis of apoB Concentrations Across Early Adulthood and Predictors for Rates of Change Using CARDIA Study Data. J Lipid Res. 2022;63(12):100299.","journal-title":"J Lipid Res"},{"key":"1449_CR49","doi-asserted-by":"crossref","unstructured":"Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326\u201333.","DOI":"10.1001\/jama.294.3.326"},{"issue":"6","key":"1449_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","volume":"1","author":"WC Cromwell","year":"2007","unstructured":"Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol. 2007;1(6):583\u201392.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1449_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","volume":"27","author":"A Sahebkar","year":"2013","unstructured":"Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013;27(6):559\u201367.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"1449_CR52","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJP. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1\/4. J Am Coll Cardiol. 2021;77(12):1564\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1449_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2013.05.010","volume":"229","author":"M Farnier","year":"2013","unstructured":"Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P. Effects of ezetimibe, simvastatin and ezetimibe\/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis. 2013;229(2):415\u201322.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1449_CR54","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/2047487319871733","volume":"27","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020;27(12):1255\u201368.","journal-title":"Eur J Prev Cardiol"},{"key":"1449_CR55","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. JACC. 2019 June 25;73(24):e285\u2013350.","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"1449_CR56","doi-asserted-by":"crossref","unstructured":"Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of Clinical Lipidology. 2021 Sept 1;15(5):629\u201348.","DOI":"10.1016\/j.jacl.2021.09.046"},{"issue":"5","key":"1449_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000509452","volume":"49","author":"YC Chou","year":"2020","unstructured":"Chou YC, Chan PC, Yang T, You SL, Bai CH, Sun CA. Apolipoprotein B Level and the Apolipoprotein B\/Apolipoprotein A-I Ratio as a Harbinger of Ischemic Stroke: A Prospective Observation in Taiwan. Cerebrovasc Dis. 2020;49(5):487\u201394.","journal-title":"Cerebrovasc Dis"},{"issue":"5\u20136","key":"1449_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000091537","volume":"21","author":"M Bhatia","year":"2006","unstructured":"Bhatia M, Howard SC, Clark TG, Neale R, Qizilbash N, Murphy MFG, et al. Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack. Cerebrovasc Dis. 2006;21(5\u20136):323\u20138.","journal-title":"Cerebrovasc Dis"},{"issue":"6","key":"1449_CR59","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s12975-025-01367-9","volume":"16","author":"F Hu","year":"2025","unstructured":"Hu F, Wu R, Zhao X, Zhao Y, Zhou J, Hu B, et al. High Apolipoprotein B Levels are Associated with an Increased Risk of Recurrent Acute Ischemic Stroke: A Nested Case\u2013Control Study. Transl Stroke Res. 2025;16(6):2035\u201346.","journal-title":"Transl Stroke Res"},{"key":"1449_CR60","doi-asserted-by":"crossref","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. ApoB and Non-HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk. Ann Neurol. 2022;92(3):379\u201389.","DOI":"10.1002\/ana.26425"},{"issue":"3","key":"1449_CR61","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. J Am Coll Cardiol. 2024;83(3):385\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1449_CR62","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/molecules28030969","volume":"28","author":"S Lampsas","year":"2023","unstructured":"Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28(3):969.","journal-title":"Molecules"},{"issue":"3","key":"1449_CR63","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308\u201319.","journal-title":"J Clin Lipidol"},{"key":"1449_CR64","doi-asserted-by":"crossref","unstructured":"Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2006;37(6):1407\u201312.","DOI":"10.1161\/01.STR.0000222666.21482.b6"},{"issue":"4","key":"1449_CR65","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","volume":"39","author":"P Arora","year":"2019","unstructured":"Arora P, Kalra R, Callas PW, Alexander KS, Zakai NA, Wadley V, et al. Lipoprotein(a) and Risk of Ischemic Stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Arterioscler Thromb Vasc Biol. 2019;39(4):810\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1449_CR66","doi-asserted-by":"crossref","unstructured":"Arnold M, Schweizer J, Nakas CT, Sch\u00fctz V, Westphal LP, Inauen C, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;7(22):2186\u201396.","DOI":"10.1093\/eurheartj\/ehab081"},{"issue":"5","key":"1449_CR67","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","volume":"29","author":"LM de Boer","year":"2022","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779\u201392.","journal-title":"Eur J Prev Cardiol"},{"key":"1449_CR68","doi-asserted-by":"crossref","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J. 2019 Sept 1;40(33):2775\u201381.","DOI":"10.1093\/eurheartj\/ehy862"},{"issue":"12","key":"1449_CR69","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"23","key":"1449_CR70","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran\u2014A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024;332(23):1992\u20132002.","journal-title":"JAMA"},{"issue":"17","key":"1449_CR71","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/14656566.2025.2601062","volume":"26","author":"B Tomlinson","year":"2025","unstructured":"Tomlinson B, Law CF. Lipoprotein(a) - treatments in development. Expert Opin Pharmacother. 2025;26(17):1831\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"20","key":"1449_CR72","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855\u201364.","journal-title":"N Engl J Med"},{"issue":"16","key":"1449_CR73","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","volume":"81","author":"WA Malick","year":"2023","unstructured":"Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2\/3. J Am Coll Cardiol. 2023;81(16):1633\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1449_CR74","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025;333(3):222\u201331.","journal-title":"JAMA"},{"key":"1449_CR75","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023;19(11):1042\u201353.","DOI":"10.1001\/jama.2023.16503"},{"issue":"2","key":"1449_CR76","first-page":"225","volume":"75","author":"M Moutachakkir","year":"2017","unstructured":"Moutachakkir M, Lamrani Hanchi A, Baraou A, Boukhira A, Chellak S. Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein. Ann Biol Clin (Paris). 2017;75(2):225\u20139.","journal-title":"Ann Biol Clin (Paris)"},{"key":"1449_CR77","unstructured":"Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. JACC [Internet]. 2025 Sept 29 [cited 2026 Jan 16]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109725075552"},{"issue":"2","key":"1449_CR78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1536\/ihj.15-346","volume":"57","author":"T Soeki","year":"2016","unstructured":"Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis. Int Heart J. 2016;57(2):134\u20139.","journal-title":"Int Heart J"},{"key":"1449_CR79","doi-asserted-by":"publisher","first-page":"1546961","DOI":"10.3389\/fendo.2025.1546961","volume":"16","author":"H Shen","year":"2025","unstructured":"Shen H, Huang A, Wang B, Huang X, Chen R. Clinical value of Lp-PLA2, LDL-C, HDL-C, hs-CRP, leukocyte, FPG and HbA1c in type 2 diabetes mellitus patients with acute ischemic stroke. Front Endocrinol (Lausanne). 2025;16:1546961.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"1449_CR80","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/archinte.166.19.2073","volume":"166","author":"MSV Elkind","year":"2006","unstructured":"Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL, High-Sensitivity C-R, Protein. Lipoprotein-Associated Phospholipase A2, and Outcome After Ischemic Stroke. Arch Intern Med. 2006;166(19):2073\u201380.","journal-title":"Arch Intern Med"},{"issue":"9670","key":"1449_CR81","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175\u201382.","journal-title":"Lancet"},{"issue":"14","key":"1449_CR82","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","volume":"76","author":"BM Everett","year":"2020","unstructured":"Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1\u03b2 and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020;76(14):1660\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"1449_CR83","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497\u2013505.","journal-title":"N Engl J Med"},{"issue":"19","key":"1449_CR84","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838\u201347.","journal-title":"N Engl J Med"},{"issue":"11","key":"1449_CR85","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S1474-4422(25)00306-0","volume":"24","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard AT, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE, et al. High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study. Lancet Neurol. 2025;24(11):920\u201330.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1449_CR86","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1161\/STROKEAHA.116.012901","volume":"47","author":"J Li","year":"2016","unstructured":"Li J, Zhao X, Meng X, Lin J, Liu L, Wang C, et al. High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. Stroke. 2016;47(8):2025\u201330.","journal-title":"Stroke"},{"issue":"10","key":"1449_CR87","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/01.STR.0000029828.51413.82","volume":"33","author":"K Winbeck","year":"2002","unstructured":"Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic Relevance of Early Serial C-Reactive Protein Measurements After First Ischemic Stroke. Stroke. 2002;33(10):2459\u201364.","journal-title":"Stroke"},{"issue":"4","key":"1449_CR88","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/01.STR.32.4.917","volume":"32","author":"M Di Napoli","year":"2001","unstructured":"Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32(4):917\u201324.","journal-title":"Stroke"},{"key":"1449_CR89","doi-asserted-by":"crossref","unstructured":"Wang Y, Li J, Pan Y, Wang M, Meng X, Wang Y. Association Between High-Sensitivity C\u2010Reactive Protein and Prognosis in Different Periods After Ischemic Stroke or Transient Ischemic Attack. J Am Heart Association. 2022;5(13):e025464.","DOI":"10.1161\/JAHA.122.025464"},{"issue":"16","key":"1449_CR90","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","volume":"343","author":"CJ Packard","year":"2000","unstructured":"Packard CJ, O\u2019Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"1449_CR91","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/01.CIR.0000154553.12214.CD","volume":"111","author":"HHS Oei","year":"2005","unstructured":"Oei HHS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke. Circulation. 2005;111(5):570\u20135.","journal-title":"Circulation"},{"issue":"7","key":"1449_CR92","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","volume":"109","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837\u201342.","journal-title":"Circulation"},{"issue":"2","key":"1449_CR93","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/STROKEAHA.107.513259","volume":"40","author":"V Nambi","year":"2009","unstructured":"Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40(2):376\u201381.","journal-title":"Stroke"},{"key":"1449_CR94","doi-asserted-by":"publisher","first-page":"858302","DOI":"10.3389\/fneur.2022.858302","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu G, Song H, Cao C, Ji X, Cao G. Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis. Front Neurol. 2022;13:858302.","journal-title":"Front Neurol"},{"issue":"8","key":"1449_CR95","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/STROKEAHA.124.046811","volume":"55","author":"M Han","year":"2024","unstructured":"Han M, Huang K, Shen C, Hu H, Liu F, Li J, et al. Discordant High Remnant Cholesterol With LDL-C Increases the Risk of Stroke: A Chinese Prospective Cohort Study. Stroke. 2024;55(8):2066\u201374.","journal-title":"Stroke"},{"issue":"42","key":"1449_CR96","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42(42):4324\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehab432 . PubMed PMID: 34293083; PubMed Central PMCID: PMC8572557.","journal-title":"Eur Heart J"},{"key":"1449_CR97","doi-asserted-by":"crossref","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019;9(1):54\u201366.","DOI":"10.1016\/j.jacc.2019.03.524"},{"issue":"1","key":"1449_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jacl.2024.11.008","volume":"19","author":"A Akinlonu","year":"2025","unstructured":"Akinlonu A, Boffa MB, Lyu C, Zhong J, Jindal M, Fadzan M, et al. Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size. J Clin Lipidol. 2025;19(1):39\u201350. PubMed PMID: 39828454; PubMed Central PMCID: PMC11908881.","journal-title":"J Clin Lipidol"},{"key":"1449_CR99","doi-asserted-by":"publisher","first-page":"e079061","DOI":"10.1136\/bmj-2023-079061","volume":"385","author":"J Li","year":"2024","unstructured":"Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024;385:e079061. https:\/\/doi.org\/10.1136\/bmj-2023-079061 . PubMed PMID: 38925803; PubMed Central PMCID: PMC11200154.","journal-title":"BMJ"},{"issue":"10448","key":"1449_CR100","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(","volume":"404","author":"P Kelly","year":"2024","unstructured":"Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. 2024;404(10448):125\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(. 24)00968-1 PubMed PMID: 38857611.","journal-title":"Lancet"},{"issue":"26","key":"1449_CR101","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","volume":"46","author":"M Samuel","year":"2025","unstructured":"Samuel M, Berry C, Dub\u00e9 MP, Koenig W, L\u00f3pez-Send\u00f3n J, Maggioni AP, et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025;46(26):2552\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf174 . PubMed PMID: 40314333; PubMed Central PMCID: PMC12233006.","journal-title":"Eur Heart J"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01449-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:00:59Z","timestamp":1784973659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01449-5","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Kelly, Schneider, Rosso, Ishida, Rostanski, and Katz have no relevant disclosures or conflicts of interest related to the submitted work.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"75"}}